de Mendoza Carmen, Garrido Carolina, Corral Angélica, Zahonero Natalia, Soriano Vincent
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
AIDS. 2008 Jan 11;22(2):311-3. doi: 10.1097/QAD.0b013e3282f4244f.
Besides I47A, mutation L76V at the HIV protease gene has recently been proposed to cause lopinavir resistance. This change was present in 37 (2.7%) out of 1376 patients failing protease inhibitor containing regimens. Although 26 (70%) were on lopinavir, most had previously failed other protease inhibitors and carried multiple protease inhibitor resistance mutations. Therefore, L76V does not appear to be a primary lopinavir resistance change when the drug is used in combination therapy.
除了I47A之外,最近有人提出HIV蛋白酶基因上的L76V突变会导致洛匹那韦耐药。在1376例含蛋白酶抑制剂方案治疗失败的患者中,有37例(2.7%)存在这种变化。虽然26例(70%)正在使用洛匹那韦,但大多数患者此前其他蛋白酶抑制剂治疗已失败,并携带多种蛋白酶抑制剂耐药突变。因此,当洛匹那韦用于联合治疗时,L76V似乎不是主要的洛匹那韦耐药变化。